MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
3.570
-0.800
-18.31%
After Hours: 3.580 +0.01 +0.28% 17:08 03/20 EDT
OPEN
4.280
PREV CLOSE
4.370
HIGH
4.400
LOW
3.515
VOLUME
234.05K
TURNOVER
--
52 WEEK HIGH
13.53
52 WEEK LOW
3.515
MARKET CAP
194.23M
P/E (TTM)
-0.7897
1D
5D
1M
3M
1Y
5Y
1D
Cantor Fitzgerald Reiterates Overweight on Alumisto Overweight
Benzinga · 17h ago
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 18h ago
Alumis Price Target Cut to $15.00/Share From $19.00 by HC Wainwright & Co.
Dow Jones · 20h ago
ALUMIS INC <ALMS.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $15 FROM $19
Reuters · 20h ago
HC Wainwright & Co. Reiterates Buy on Alumis, Lowers Price Target to $15
Benzinga · 20h ago
Alumis reports FY results
Seeking Alpha · 1d ago
ALUMIS REPORTS YEAR END 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACHIEVEMENTS
Reuters · 1d ago
Press Release: Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
Dow Jones · 1d ago
More
About ALMS
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.